Abstract
Modeling and Simulation (M&S) can be a key factor in efficient drug development. It is well recognized that collaboration of multiple disciplines is critical to the success of M&S in supporting drug development decisions. This chapter provides guidance on how the main collaborators (biostatistics, clinical research and clinical PK-PD) can achieve co-ownership of M&S efforts to make better informed decisions on trial designs. The clinical development program of corifollitropin alfa is presented as an example of successful model-based drug development. Throughout a long-lasting collaborative effort, biostatistics and clinical PK-PD scientists have learned to appreciate each other’s methods, all collaborators have shared their expertise to integrate physiological and pharmacological concepts with clinical data and clinical research has started to pro-actively conduct model-informed trials. Cultural barriers and logistical difficulties were overcome, resulting in an organizational structure that ensures better informed decisions on trial designs and more efficient drug development.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Burman CF, Hamrén B, Olsson P (2005) Modeling and simulation to improve decision-making in clinical development. Pharmaceut Statist 4:47–58
de Greef R, de Haan AFJ, Marintcheva-Petrova M, Mannaerts BMJL. (2008) Integrating PK-PD and statistics to support decision making in clinical drug development of corifollitropin alfa: a case study in controlled ovarian stimulation. American Conference on Pharmacometrics, Tucson, AZ, USA. Abstract has been published on website: http://tucson2008.go-acop.org/pdfs/Abstract_de_Greef.pdf
de Greef R, Zandvliet AS, de Haan AFJ, IJzerman-Boon PC, Marintcheva-Petrova M, Mannaerts BMJL (2010) Dose selection of corifollitropin alfa in controlled ovarian stimulation using modeling and simulation. Clin Pharmacol Ther 88(1):79–87
De Ridder F (2005) Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development. Basic Clin Pharmacol Toxicol 96:235–241
Devroey P, Boostanfar R, Koper NP, Mannaerts BM, IJzerman-Boon PC, Fauser BC (2009) A double-blind, noninferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 24:3063–3072
Devroey P, Fauser BC, Platteau P, Beckers NG, Dhont M, Mannaerts BM (2004) Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 89:2062–2070
Duijkers IJ, Klipping C, Boerrigter PJ, Machielsen CS, De Bie JJ, Voortman G (2002) Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. Hum Reprod 17:1987–1993
Grasela TH, Dement CW, Kolterman OG, Fineman MS, Grasela DM, Honig P, Antal EJ, Bjornsson TD, Loh E (2007) Pharmacometrics and the transition to model-based development. Clin Pharmacol Ther 82:137–142
Krzyzanski W, Jusko WJ (1998) Integrated functions for four basic models of indirect pharmacodynamic response. J Pharm Sci 87:67–72
Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, Corrigan BW, Lockwood PA, Marshall SA, Benincosa LJ, Tensfeldt TG, Parivar K, Amantea M, Glue P, Koide H, Miller R (2007) Model-based drug development. Clin Pharmacol Ther 82:21–32
Sheiner LB (1997) Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61:275–291
The corifollitropin alfa dose-finding study group (2008) A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Hum Reprod 23:2484–2492
The corifollitropin alfa ENSURE study group (2010) Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower body-weight women. Reproductive BioMedicine Online 21(1):66–76
Wakelkamp M, Alvan G, Gabrielsson J, Paintaud G (1996) Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. Clin Pharmacol Ther 60:75–88
Zhang L, Pfister M, Meibohm B (2008) Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J 10:552–559
Acknowledgments
George Borm, Martin Struijs, Huub Jan Kleijn, Michiel van den Heuvel, Norbert Koper, Klaas Prins.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Zandvliet, A.S. et al. (2011). Keys of Collaboration to Enhance Efficiency and Impact of Modeling and Simulation. In: Kimko, H., Peck, C. (eds) Clinical Trial Simulations. AAPS Advances in the Pharmaceutical Sciences Series, vol 1. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7415-0_7
Download citation
DOI: https://doi.org/10.1007/978-1-4419-7415-0_7
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-7414-3
Online ISBN: 978-1-4419-7415-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)
